Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial.
Saved in:
| Title: | Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial. |
|---|---|
| Authors: | Durovni B; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil., Cordeiro-Santos M; Fundação de Medicina Tropical 'Doutor Heitor Vieira Dourado', Manaus, Brazil.; Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil.; Pós-Graduação em Saúde e Inovação, Universidade Nilton Lins, Manaus, Amazonas, Brazil., Cavalcante SC; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil., Spener-Gomes R; Fundação de Medicina Tropical 'Doutor Heitor Vieira Dourado', Manaus, Brazil.; Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil.; Faculdade de Medicina, Universidade Federal do Amazonas, Manaus, Brazil., Garcia J; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil., Cohn S; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Saraceni V; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil., Kohler B; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Moulton LH; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America., Brito da Souza A; Fundação de Medicina Tropical 'Doutor Heitor Vieira Dourado', Manaus, Brazil., Berihun A; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America., Marzinke M; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Chaisson RE; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. |
| Corporate Authors: | Ultra Curto Study Team |
| Source: | PLoS medicine [PLoS Med] 2026 Feb 10; Vol. 23 (2), pp. e1004758. Date of Electronic Publication: 2026 Feb 10 (Print Publication: 2026). |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase IV; Multicenter Study; Comparative Study |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41666121 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Durovni+B%22">Durovni B</searchLink>; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Cordeiro-Santos+M%22">Cordeiro-Santos M</searchLink>; Fundação de Medicina Tropical 'Doutor Heitor Vieira Dourado', Manaus, Brazil.; Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil.; Pós-Graduação em Saúde e Inovação, Universidade Nilton Lins, Manaus, Amazonas, Brazil.<br /><searchLink fieldCode="AU" term="%22Cavalcante+SC%22">Cavalcante SC</searchLink>; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Spener-Gomes+R%22">Spener-Gomes R</searchLink>; Fundação de Medicina Tropical 'Doutor Heitor Vieira Dourado', Manaus, Brazil.; Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil.; Faculdade de Medicina, Universidade Federal do Amazonas, Manaus, Brazil.<br /><searchLink fieldCode="AU" term="%22Garcia+J%22">Garcia J</searchLink>; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Cohn+S%22">Cohn S</searchLink>; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Saraceni+V%22">Saraceni V</searchLink>; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Kohler+B%22">Kohler B</searchLink>; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Moulton+LH%22">Moulton LH</searchLink>; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Brito+da+Souza+A%22">Brito da Souza A</searchLink>; Fundação de Medicina Tropical 'Doutor Heitor Vieira Dourado', Manaus, Brazil.<br /><searchLink fieldCode="AU" term="%22Berihun+A%22">Berihun A</searchLink>; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Marzinke+M%22">Marzinke M</searchLink>; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Chaisson+RE%22">Chaisson RE</searchLink>; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22Ultra+Curto+Study+Team%22">Ultra Curto Study Team</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101231360%22">PLoS medicine</searchLink> [PLoS Med] 2026 Feb 10; Vol. 23 (2), pp. e1004758. <i>Date of Electronic Publication: </i>2026 Feb 10 (<i>Print Publication: </i>2026). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase IV; Multicenter Study; Comparative Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101231360 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-1676 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215491277%22">15491277 </searchLink><i>NLM ISO Abbreviation: </i>PLoS Med <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41666121 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1371/journal.pmed.1004758 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e1004758 Titles: – TitleFull: Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Durovni B – PersonEntity: Name: NameFull: Cordeiro-Santos M – PersonEntity: Name: NameFull: Cavalcante SC – PersonEntity: Name: NameFull: Spener-Gomes R – PersonEntity: Name: NameFull: Garcia J – PersonEntity: Name: NameFull: Cohn S – PersonEntity: Name: NameFull: Saraceni V – PersonEntity: Name: NameFull: Kohler B – PersonEntity: Name: NameFull: Moulton LH – PersonEntity: Name: NameFull: Brito da Souza A – PersonEntity: Name: NameFull: Berihun A – PersonEntity: Name: NameFull: Marzinke M – PersonEntity: Name: NameFull: Chaisson RE IsPartOfRelationships: – BibEntity: Dates: – D: 10 M: 02 Text: 2026 Feb 10 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1549-1676 Numbering: – Type: volume Value: 23 – Type: issue Value: 2 Titles: – TitleFull: PLoS medicine Type: main |
| ResultId | 1 |
